Study about perception of Parkinson's disease progression among patients with Parkinson's disease and physicians in Japan

Study about perception of Parkinson's disease progression among patients with Parkinson's disease and physicians in Japan - Study about perception of Parkinson's disease progression among patients with Parkinson's disease and physicians

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032542

Enrollment

210

Registered

2018-05-13

Start date

2018-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients, who fulfill the following criteria, can be included: -Adult patients with confirmed diagnosis of PD who receive any PD treatments for more than 1 year, continuously. -Willingness and ability to sign informed consent. Physicians, who fulfill the following criteria, can be included: -Who have more than five patients with PD matching the criteria above -Willingness and ability to provide informed consent

Exclusion criteria

Exclusion criteria: -Patients who are not able to complete the questionnaires by themselves and have no support for questionnaire completion by their caregivers. -Patients and physicians who cannot submit the questionnaire in 14 days after the appointment.

Design outcomes

Primary

Measure	Time frame
The proportion of individuals reporting current Wearing-off(WO) as recognized by Wearing-off Questionnaire performed by patients and physician's judgment.	—

Secondary

Measure	Time frame
The main secondary endpoints are as follows: -The proportion of individuals reporting morning akinesia among patients and physicians -The patient's QOL assessed among patients and physicians	—

Countries

Japan

Contacts

Public ContactJun Watanabe

AbbVie GK Medical Affairs

jun.watanabe@abbvie.com03-4577-1111

Outcome results